UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 15, 2015
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
Nevada |
|
000-53605 |
|
26-1265381 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
400
Water Street, Suite 200, Rochester, MI |
|
48307 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: 248-651-6568
|
|
|
|
(Former
name or former address, if changed since last report) |
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION
7 – Regulation FD Disclosure
Item 7.01 |
Regulation FD Disclosure |
On December
15, 2015, we issued a press release concerning the appointment of James Brooks to the new position of senior vice president of
business development. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information
in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
SECTION
9 – Financial Statements and Exhibits
Item 9.01 |
Financial Statements and Exhibits |
99.1 |
Press release, dated December 15, 2015 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OptimizeRx
Corporation |
|
|
Date: December
15, 2015 |
/s/
Doug Baker |
|
Doug Baker
Chief Financial Officer |
3
Exhibit 99.1
OptimizeRx
Corporation Appoints James Brooks as SVP of Business Development
Dec
15, 2015
OTC
Disclosure & News Service
OptimizeRx
Corporation Appoints James Brooks as SVP of Business Development
ROCHESTER,
MI--(Marketwired - December 15, 2015) - OptimizeRx Corp. (OTCQB: OPRX), a software company whose premier content-delivery platform
enables pharmaceutical companies to provide on-demand patient-care services, has appointed James Brooks to the new position of
senior vice president of business development, effective January 4, 2016.
"James'
extensive executive sales and marketing experience, particularly his track record of growing the topline and sales leadership
at FORTUNE 500 and electronic health record companies, makes him a great fit with OptimizeRx," said David Harrell, the company's
CEO. "James will champion our EHR business through development of new relationships with other EHR providers and patient
platforms. He brings to us numerous relationships within large EHRs that can be leveraged to integrate OptimizeRx savings and
support to reach more doctors and patients."
The
company recently announced an expansion of its relationship with Allscripts, who will work with OptimizeRx exclusively to manage
their patient savings across all of their electronic health record (EHR) platforms, including their largest platform, Touchworks,
which will be integrated in 2016.
OptimizeRx's
network is the largest of its kind, with more than 350 leading EHRs engaging more healthcare providers at the 'point-of-prescribe'
than any other network to provide sample vouchers, copay savings and other patient support that is automated for doctors and pharmacists.
James
Brooks Bio
Brooks
brings more than 20 years of experience in sales & marketing, including sales force development, sales management, and organizational
leadership processes within the Electronic Health Record (EHR) and Healthcare Technology sector.
Prior
to joining OptimizeRx, he served as chief revenue officer at iCare, an enterprise cloud EHR and revenue cycle management system
vendor.
Prior
to iCare, Brooks served as executive vice president at Modernizing Medicine, a leading provider of EHR systems focused on the
dermatology, ophthalmology, plastic, and orthopedic marketplace. While at Modernizing Medicine, he was responsible for developing
and managing a world-class sales and marketing team and grew the business into one of the largest specialty EHRs.
Brooks
additionally served as vice president of the enterprise sales and radiology division at Sage North America, a provider of information
systems with a focus on healthcare with $300 million in annual revenue and 1,200 staff members.
Earlier
in his career, he served as senior sales executive and enterprise vice president of clinical sales at McKesson, a FORTUNE 500
company delivering healthcare services and information technology.
Brooks
holds a Bachelor of Arts in Economics and Speech Communication from St. Cloud State University in Minnesota.
About
OptimizeRx Corporation
OptimizeRx Corporation (OTCQB: OPRX) provides unique consumer and physician platforms to help patients better afford and
comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to
expand awareness, access and adherence to their medications.
The
company's core product, SampleMD™, replaces drug samples with electronic trial vouchers and copay coupon savings, which
are added to an e-Prescription and electronically sent to the pharmacy. SampleMD is integrated within leading Electronic Health
Record (EHR) platforms, including Allscripts, Quest Diagnostics, Practice Fusion and over 350 other EHRs.
OptimizeRx's
proprietary technology reaches over 250,000 healthcare providers. In turn, the company promotes patient savings and support from
the world's largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information,
visit www.optimizerxcorp.com.
Important
Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as
amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make
an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements,
which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties
to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition
and other material risks.
Company
Contact:
OptimizeRx
Doug Baker
Email contact
248-651-6568 x807
Investor Relations Contact:
Liolios Group
Ron Both
Senior Managing Director
Email contact
949-574-3860
Copyright
© 2015 Marketwired. All Rights Reserved
The
above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and
not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024